重组人血管内皮抑素在非小细胞肺癌患者肿瘤血管正常化时间窗研究

摘要

目的 重组人血管内皮抑素(恩度)在非小细胞肺癌(non-small cell lung cancer,NSCLC)患者中存在肿瘤血管正常化时间窗,但是目前各家报道结果不一致,因此本研究采用CT灌注扫描方法研究重组人血管内皮抑素治疗NSCLC的肿瘤血管正常化时间窗.方法 对30例不能手术的NSCLC患者进行重组人血管内皮抑素治疗,分为3组,每组各10例,分别于用药前、用药后1~3天及用药后4~7天进行CT灌注扫描,通过计算血流量(blood flow,BF)、血容量(blood volume,BV)、对比剂通过时间(mean transis time,MTT)、表面通透性(permeability surface,PS)等参数,研究重组人血管内皮抑素治疗NSCLC的肿瘤血管正常化时间窗.结果 通过对重组人血管内皮抑素治疗NSCLC在不同时间的CT灌注扫描参数,确定重组人血管内皮抑素治疗NSCLC的肿瘤血管正常化时间窗为用药后1~3天.结论 重组人血管内皮抑素在NSCLC患者肿瘤血管正常化的时间窗为用药后1~3天,可为联合其他治疗提供参考.%Objective The recombinant human endostatin (endostar) in non-small cell lung cancer (NSCLC) have a vascular normalization window, but inconsistent results from the literature reports, so this study uses CT perfusion scanning method to research vascular normalization window. Method 30 inoperable NSCLC patients were randomly divided into three groups and each group with 10 cases: group 1 (before transfusion of endostar), group 2 (transfusion of endostar for 1 to 3 days), group 3 (transfusion of endostar for 4 to 7 days).The CT perfusion scan of the chest was followed up after treatment, the parameter include: blood flow, blood volume, mean transis time, permeability surface were observed, to study the vascular normalization window of recombinant human endostatin in NSCLC. Result By the parameter of CT perfusion scan in recombinant human endostatin (endostar) treatment NSCLC, determine the vascular normalization window was 1 to 3 days. Conclusion The vascular normalization window with recombinant human endostatin in NSCLC is 1 to 3 days.